| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Gilead Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 45%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $229,600, and 10, calls, for a total amount of $1,131,181.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $135.0 for Gilead Sciences, spanning the last three months.
In today's trading context, the average open interest for options of Gilead Sciences stands at 1364.33, with a total volume reaching 11,357.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $100.0 to $135.0, throughout the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | TRADE | BEARISH | 01/16/26 | $2.48 | $2.26 | $2.32 | $135.00 | $765.3K | 1.1K | 3.9K |
| GILD | PUT | TRADE | BULLISH | 02/20/26 | $3.45 | $3.2 | $3.28 | $115.00 | $229.6K | 268 | 704 |
| GILD | CALL | SWEEP | BEARISH | 01/16/26 | $2.37 | $2.36 | $2.36 | $135.00 | $70.8K | 1.1K | 684 |
| GILD | CALL | TRADE | BEARISH | 11/21/25 | $3.1 | $2.76 | $2.84 | $124.00 | $56.8K | 5.8K | 443 |
| GILD | CALL | TRADE | BULLISH | 11/21/25 | $2.51 | $2.34 | $2.5 | $124.00 | $49.7K | 5.8K | 545 |
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Having examined the options trading patterns of Gilead Sciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $131.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $145. * Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Gilead Sciences with a target price of $125. * An analyst from RBC Capital has decided to maintain their Sector Perform rating on Gilead Sciences, which currently sits at a price target of $105. * Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Gilead Sciences with a target price of $140. * An analyst from Scotiabank downgraded its action to Sector Outperform with a price target of $140.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from Benzinga Pro.
Posted In: GILD
